Analyst Price Target is $12.08
▲ +207.46% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for TriSalus Life Sciences in the last 3 months. The average price target is $12.08, with a high forecast of $16.00 and a low forecast of $10.00. The average price target represents a 207.46% upside from the last price of $3.93.
Current Consensus is
Buy
The current consensus among 8 contributing investment analysts is to buy stock in TriSalus Life Sciences.
TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.
Read More
